AstraZeneca Pharma P/E Ratio
Current P/E Ratio
86.7
High Valuation
Very High - High growth expectations or significantly overvalued
AstraZeneca Pharma P/E ratio. AstraZeneca Pharma (ASTRAZEN) P/E ratio is 86.7 (High), EPS (TTM) ₹75.01, current price ₹6113.00 on NSE — Very High - High growth expectations or significantly overvalued. Also explore AstraZeneca Pharma stock price data download to track price trends across different timeframes.
Current Valuation Metrics
P/E Ratio
86.7
Current Price
₹6113.00
EPS (TTM)
₹75.01
Exchange
NSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
52.06
Sector Median
29.4
Sector Rank
#11 of 255
Sector Percentile
4.3%
ASTRAZEN P/E Ratio — Valuation Signal & Historical Context
AstraZeneca Pharma P/E 86.7 — signal: Overvalued. For live price, revenue and the complete fundamental profile, see AstraZeneca Pharma share price chart.
- Stock appears overvalued with PE of 86.7, suggesting caution for new investments
- Trading at premium to sector average PE of 52.06
ASTRAZEN vs Healthcare Peers — P/E Ratio Comparison
AstraZeneca Pharma P/E 86.7 vs Healthcare average 52.06, median 29.4 — range 2.0–733.0.
Sector Average
52.06
Sector Median
29.4
Lowest P/E
2.0
Highest P/E
733.0
Companies
255
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.0 | ₹72 | Low |
| Brooks Laboratories | BROOKS | 2.6 | ₹206 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.3 | ₹54 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.1 | ₹6,355 | Low |
| Dipna Pharmachem | DPL | 4.5 | ₹11 | Low |
| JFL Life Sciences | JFLLIFE | 4.7 | ₹82 | Low |
| Royal Sense | ROYAL | 4.8 | ₹34 | Low |
| Star Imaging And Path Lab | STARIMAGIN | 5.3 | ₹110 | Low |
| Kabra Drugs | KABRADG | 6.3 | ₹49 | Low |